VANI

Company Overview — What Does Vivani Medical, Inc. Do?

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California. Vivani Medical, Inc. (VANI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Adam Mendelsohn and employs approximately 20 people, headquartered in SYLMAR, California. With a market capitalization of $85M, VANI is one of the notable companies in the Healthcare sector.

Vivani Medical, Inc. (VANI) Stock Rating — Avoid (April 2026)

As of April 2026, Vivani Medical, Inc. receives a Avoid rating with a composite score of 28.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.VANI ranks #4,099 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Vivani Medical, Inc. ranks #721 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VANI Stock Price and 52-Week Range

Vivani Medical, Inc. (VANI) currently trades at $1.04. The 52-week high for VANI is $1.92, which means the stock is currently trading -45.8% from its annual peak. The 52-week low is $0.91, putting the stock 14.9% above its annual trough. Recent trading volume was 115K shares, suggesting relatively thin trading activity.

Is VANI Overvalued or Undervalued? — Valuation Analysis

Vivani Medical, Inc. (VANI) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.70x, versus the sector average of 2.75x.

At current multiples, Vivani Medical, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Vivani Medical, Inc. Profitability — ROE, Margins, and Quality Score

Vivani Medical, Inc. (VANI) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -165.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -66.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VANI Debt, Balance Sheet, and Financial Health

Vivani Medical, Inc. has a debt-to-equity ratio of 150.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.71x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $3M.

VANI has a beta of 0.74, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Vivani Medical, Inc. is 43/100, reflecting average volatility within the normal range for its sector.

Vivani Medical, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Vivani Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-26M. Operating income came in at $-27M.

In FY 2025, Vivani Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-27M. Operating income came in at $-28M.

In Q3 2025, Vivani Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-7M. Operating income came in at $-7M.

In Q2 2025, Vivani Medical, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.12. Net income for the quarter was $-7M. Operating income came in at $-7M.

Over the past 8 quarters, Vivani Medical, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing VANI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VANI Dividend Yield and Income Analysis

Vivani Medical, Inc. (VANI) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VANI Momentum and Technical Analysis Profile

Vivani Medical, Inc. (VANI) has a momentum factor score of 35/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

VANI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Vivani Medical, Inc. (VANI) ranks #721 out of 838 stocks based on the Blank Capital composite score. This places VANI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VANI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VANI vs S&P 500 (SPY) comparison to assess how Vivani Medical, Inc. stacks up against the broader market across all factor dimensions.

VANI Next Earnings Date

No upcoming earnings date has been announced for Vivani Medical, Inc. (VANI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VANI? — Investment Thesis Summary

The quantitative profile for Vivani Medical, Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Momentum is weak at 35/100, a headwind for near-term performance.

In summary, Vivani Medical, Inc. (VANI) earns a Avoid rating with a composite score of 28.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VANI stock.

Related Resources for VANI Investors

Explore more research and tools: VANI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VANI head-to-head with peers: VANI vs AZN, VANI vs SLGL, VANI vs VMD.